近年来，一种被称为抗体偶联药物（Antibody-Drug Conjugate, ADC）的新型抗癌药在临床实践中不断取得突破进展，使其在全球创新药领域迅速崛起。ADC 是一种什么样的药物？它为何能成为抗癌的新希望呢？

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

近几年，抗体-药物偶联物（Antibody-Drug Conjugate，ADC）已成为发展最为迅猛的抗肿瘤药物赛道之一。在介绍许多新型 ADC 时，常常强调其具备高载荷、高药物与抗体比率、可裂解连接子等一系列显著优势。然而，大部分肿瘤医师并未系统学习过 ADC 研发相关技术，对于这类药物的介绍往往一知半解。在 ADC ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

近日，全球医药巨头礼来公司宣布其开发的Nectin-4靶向抗体药物偶联物（ADC）在中国获得了国家药品监督管理局（NMPA）的临床试验批准。这一消息不仅为国内癌症患者带来了新的希望，也标志着中国在国际生物医药领域内的影响力正在逐步增强。

你是否听说过ADC药物？这种被称为‘魔法子弹’的抗癌新药正在改变癌症治疗的未来。2025年，科伦博泰生物将迎来商业化元年，其核心产品陆续获批上市，标志着国产ADC药物从‘跟跑’迈向‘并跑’。本文将带您深入了解这一领域的创新进展和未来潜力。

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload ...

Therefore, the rising population of various oncological disorders is one of the key drivers for the antibody drug conjugate market. Driven by the availability of innovative technology platforms ...

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...